Business
New Clinical and Preclinical Data for Investigational Candidate Zidesamtinib Presented at AACR Annual Meeting 2026
Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced new clinical and preclinical data for zidesamtinib, an investigational ROS1-selective inhibitor, to be presented during poster sessions at the American Association for Cancer Research (AACR) Annual Meeting 2026 being held April 17-22 in San Diego.
About this update from Nuvalent, Inc.
[{"type":"text","content":"Zidesamtinib demonstrated meaningful clinical activity in subset of TKI pre-treated ROS1-positive NSCLC patients from ARROS-1 trial previously treated with repotrectinib or taletrectinib, including in those with CNS disease or ROS1 resistance mutations","length":252,"tagName":"p","attribs":{}},{"type":"text","content":"Preclinical data support differentiated brain penetrance and intracranial activity as compared to repotrectinib and taletrectinib","length":129,"tagName":"p","attribs":{}},{"type":"text","content":"CAMBRIDGE, Mass., April 17, 2026 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced new clinical and preclinical data for zidesamtinib, an investigational ROS1-selective inhibitor, to be presented during poster sessions at the American Association for Cancer Research (AACR) Annual Meeting 2026 being held April 17-22 in San Diego.","length":498,"tagName":"p"},{"type":"image","alt":"Nuvalent, Inc. (PRNewsfoto/Nuvalent, Inc.)","displaySize":"","headline":null,"caption":"Nuvalent, Inc. (PRNewsfoto/Nuvalent, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":119,"url":"https://media.zenfs.com/en/prnewswire.com/006d4b5652d5dd7204d997761f53cb52"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/RCK_1lPKTaWgCmt5M44.EA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTIxMA--/https://media.zenfs.com/en/prnewswire.com/006d4b5652d5dd7204d997761f53cb52","width":400,"height":119}},"href":"https://mma.prnewswire.com/media/1583941/Nuvalent_Inc_Logo_2024.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""The strong patient enrollment in our ARROS-1 trial has reflected meaningful investigator enthusiasm for zidesamtinib's profile and generated a robust data set that enables deep characterization of its activity for patients with ROS1-positive NSCLC beyond our initial pivotal data presentation," said James Porter, Ph.D., Chief Executive Officer at Nuvalent. "We're highly encouraged by these clinical data for patients previously treated with repotrectinib or taletrectinib in our ARROS-1 trial, which we believe further reinforce the medical needs that remain for patients with ROS1-positive NSCLC despite th...